Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gliclazide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.77 |
| ▸ | LMNA | P02545 | 4/20 | 0.77 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.69 |
| ▸ | TSHR | P16473 | 2/20 | 0.69 |
| ▸ | ALB | P02768 | 1/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.53 |
| ▸ | FBP1 | P09467 | 7/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gliclazide SCHEMBL16387 | 0.88 | ALDH1A1 (1.00) | ALDH1A1LMNAAKR1C3CYP2C9TSHR | |
| Gliclazide SCHEMBL291434 | 0.88 | ALDH1A1 (1.00) | ALDH1A1LMNAAKR1C3CYP2C9TSHR | |
| Gliclazide SCHEMBL1537023 | 0.88 | ALDH1A1 (1.00) | ALDH1A1LMNAAKR1C3CYP2C9TSHR | |
| Gliclazide SCHEMBL239075 | 0.87 | ALDH1A1 (0.97) | ALDH1A1LMNAAKR1C3CYP2C9TSHR | |
| Tolazamide SCHEMBL992662 | 0.85 | ALDH1A1 (0.75) | ALDH1A1LMNAAKR1C3CYP2C9TSHR | |
| Gliclazide SCHEMBL30011556 | 0.84 | ALDH1A1 (0.86) | ALDH1A1LMNAAKR1C3CYP2C9TSHR | |
| Tolbutamide SCHEMBL15918 | 0.83 | ALDH1A1 (1.00) | ALDH1A1LMNACYP2C9TSHRALB | |
| Tolbutamide SCHEMBL1536920 | 0.83 | ALDH1A1 (1.00) | ALDH1A1LMNACYP2C9TSHRALB | |
| Gliclazide SCHEMBL6344915 | 0.82 | ALDH1A1 (0.88) | ALDH1A1LMNAAKR1C3TSHRCYP3A4 | |
| Tolbutamide SCHEMBL11357518 | 0.82 | ALDH1A1 (0.97) | ALDH1A1LMNACYP2C9TSHRALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013102921-A2 | HCG - NEWER TREATMENT MODALITY FOR TYPE 2 DIABETES MELLITUS (T2DM) | SANZYME LIMITED (IN) | 2013-07-11 | — | — | WO | claimed |
| WO-2013102921-A2 | HCG - NEWER TREATMENT MODALITY FOR TYPE 2 DIABETES MELLITUS (T2DM) | SANZYME LIMITED (IN) | 2013-07-11 | — | — | WO | disclosed |
| WO-2011069197-A1 | INHALABLE FORMULATIONS | THE UNIVERSITY OF SYDNEY (AU) | 2011-06-16 | — | — | WO | disclosed |